"I was delighted to take part in a clinical trial as it has the potential to really help others in the future.”
A trial looking at the order in which everolimus and sunitinib should be given for advanced kidney cancer (RECORD 3)
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
This trial compared 2 different orders (sequences) of having everolimus and sunitinib for kidney cancer that had spread to other parts of the body. It was for people who had the most common type of kidney cancer called renal cell cancer.
In this trial they compared giving a drug called everolimus (also known as Afinitor) before sunitinib with giving everolimus after sunitinib. Everolimus is also a type of biological therapy. It stops a particular protein called
Some people had sunitinib to begin with and then if their cancer got worse, they stopped that and started everolimus. Some people started treatment with everolimus and then changed to sunitinib if their cancer got worse.
The aims of the study were to
- See which was the best order to give everolimus and sunitinib for kidney cancer that had spread
- Learn more about the side effects of both treatments and the effect they had on
quality of life
Summary of results
The trial team found that giving everolimus before sunitinib didn’t work as well as giving sunitinib before everolimus to treat kidney cancer that had spread.
This was an international phase 2 trial. It was a randomised trial. The 471 people who took part were put into 1 of 2 treatment groups. Neither they nor their doctor could choose which group they were in.
- 238 people had everolimus first followed by sunitinib
- 233 people had sunitinib first followed by everolimus
When the researchers looked at the average length of time people lived without any sign of their cancer getting worse they found it was
- Just over 8 months for those who had everolimus first then sunitinib
- Just under 11 months for those who had sunitinib first then everolimus
When their cancer got worse, just under half of the people in each group followed on with their treatment and changed over to other drug.
The researchers then looked at the average overall length of time people lived, they found it was
- Just under 22½ months for those who had everolimus first followed by sunitinib
- 32 months for those who had sunitinib first followed by everolimus
The most common side effects of both everolimus and sunitinib as first treatments were
- Sore mouth
- Tiredness (fatigue)
The trial team concluded that as a first treatment for kidney cancer that has spread everolimus was not as good as sunitinib. So having sunitinib first followed by everolimus when the cancer got worse should remain the
We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Dr Amit Bahl
NIHR Clinical Research Network: Cancer